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Abstract
 .Immunoliposomes composed of hydrogenated soy phosphatidylcholine, cholesterol, methoxypoly ethylene glycol -dis-
 .  .tearoyl phosphatidylethanolamine mPEG-DSPE , and hydrazide-PEG-DSPE mole ratio, 57:38:3.3:1.7 linked to
 .periodate-oxidized chimerized mouse IgG C225, anti-human epidermal growth factor receptor were prepared by an
optimized aggregation-free procedure. The antigen-binding activity of the immunoliposomes was well preserved. When
 .injected intravenously into naive rats, the immunoliposomes ;18 IgG per 100 nm liposome exhibited long circulation
 .times MRTs8.5 h, Cls0.2 mlrh . Subsequent injections of the immunoliposomes into the same animals resulted in
 .rapid clearance MRTF0.7 h, ClG7 mlrh , which was accompanied by a significant increase in anti-C225 specific titers.
Upon repeated injection or coinjection with the parent liposomes free C225 consistently exhibited prolonged circulation
without any increase in C225-specific antisera, but was cleared quickly when administered into animals that had been
pretreated with the immunoliposomes. Screening of the immunoliposome induced antisera against human polyclonal IgG
and C225-derived FabX fragment revealed that the immune response was specifically triggered by the constant human region
of C225. These results demonstrate that the preparations of PEG-grafted immunoliposomes are more immunogenic than the
free IgG component, which is of profound importance to the antibody-mediated liposomal drug delivery effort. q 1997
Elsevier Science B.V.
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1. Introduction
Recent development of unilamellar lipid vesicles
 .liposomes containing external surface-grafted
 .  .poly ethylene glycol PEG chains holds a great
w xpromise for liposomal drug delivery 1 . PEG-grafted
liposomes exhibit dose-independent long-circulating
blood lifetimes, reduced uptake by organs of
 .mononuclear phagocyte system liver and spleen ,
w xand enhanced accumulation in tumors 2–5 . These
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properties are in striking contrast to those of classical
 .non PEG-containing liposomal preparations, which
are quickly removed from the circulation by the liver,
limiting their use for systemic drug delivery. For
similar reasons, antibody-mediated targeting of clas-
sical liposomes have been disappointing. In the last
several years a number of advances have taken place
in methodologies for preparation of PEG-grafted im-
 w x.munoliposomes for review, see ref. 6 . It is be-
lieved that since PEG-liposomes persist in circulation
for a long period of time there should be a better
opportunity for the liposome-bound antibody to en-
counter its target and thus result in better accumula-
tion at that site. Several approaches to the preparation
of PEG-grafted immunoliposomes have been ex-
plored by various groups of investigators. We favor
the methodology of linking antibodies to the distal
ends of liposomal surface-grafted PEG chains for two
w xreasons 7–10 . This should minimize interference of
 .the polymer chains: A in antibody–antigen interac-
 .tion, and also B in conjugation reactions, i.e. the
coupling of antibodies to liposomes. Both phenomena
were observed when antibodies were conjugated to
polar head groups of phospholipid components of
w xPEG-grafted liposomes 3,10,11 . To explore the dis-
Fig. 1. Schematic depiction of the immunoliposome formation
tal end coupling, several end-group functionalized
wPEG–lipid conjugates were introduced recently 8–
x10,12–14 . These derivatives incorporated into lipo-
somes allow for facile coupling of immunoglobulins,
often with good preservation of antigen-binding ac-
tivity. Thus the field of PEG-grafted immunolipo-
somes is now well positioned for accumulation of in
vivo data which should provide a true measure of the
value of this approach. A number of animal models
have been already investigated with different formu-
lations of PEG-immunoliposomes, examining such
variables as particle size, coupling chemistry, anti-
body density, density of the grafted polymer, and the
ability to deliver increased quantities of drug to the
w xtarget sites 3,9–11,15–17 . Although immunogenic-
ity of classical liposomes and immunoliposomes has
w x been studied extensively 18–22 for reviews, see
w x.refs. 23,24 , this important parameter as it pertains
to the PEG-containing immunoliposomes has thus far
w x 1received little attention 25 .
It is relevant to note that the experience with
PEG-proteins shows that the polymer conjugation
w xoften results in reduced immunogenicity 27,28 and
in some cases even induces tolerance to the protein
w xcomponent of the conjugate 29 .
In this manuscript we present the results of our
experiments with preparations of liposomes bearing
residues of chimeric monoclonal antibody to the
 .EGFR C225 covalently attached through their
carbohydrate moieties to hydrazide end-groups of
PEG chains grafted onto the liposomal surface Fig.
.1 . In vivo experiments were designed to gain an
insight into issue of immunogenicity of PEG-im-
munoliposomes. In particular, we studied immunoli-
posome formulations optimized to exhibit extended
circulation lifetimes while retaining antigen binding
ability. After repeated i.v. injections in rats these
formulations consistently exhibited rapid clearance
1 w xAnother reference 26 in which a ,v-bis-stearoyl-PEG400
was used in immunoliposome formulations to enhance their
adjuvanticity, was brought to our attention by one of the review-
ers. The derivative used contained stearate ester positioned at
both termini of short oligoethylene glycol fragment average
.length 9 oxyethylene units . It is not capable of steric stabiliza-
tion nor of conveyance of long-circulating properties to its lipo-
somes. Thus the relevance of this PEG-derivative and its formula-
tions to the current work is marginal.
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from the bloodstream with concomitant increase in
antisera titers specific to C225. To the best of our
knowledge, this is the first study examining the im-
munogenicity of PEG-immunoliposomes constructed
by a well-defined, aggregation-free chemistry. The
results have important implications for antibody-
mediated liposomal drug delivery.
2. Experimental procedures
2.1. Materials and methods
Hz-PEG-DSPE and mPEG-DSPE were synthe-
sized from PEG and mPEG, both of molecular weight
 . w x2000 Da Fluka as described in detail elsewhere 12 .
a  .Sodium periodate, N -acetyl-methionine NAM ,
cholesterol, desferoxamine mesylate, Human IgG, and
 .BSA were purchased from Sigma St. Louis, MO .
 .Hydrogenated soy phosphatidylcholine HSPC was
 .obtained from Lipoid Ludwigshafen, Germany . The
Sepharose CL-4B size exclusion gel was from Phar-
macia. The radiochemicals Na125I and 67Ga citrate
were obtained from Amersham, Arlington, IL, and
Syncor International Corp., Chatsworth, CA, respec-
tively. The 96-well plates used for the ELISA assay
were Immulon 1 from Dynatech Laboratories, Chan-
tilly, VA. Human clinical grade C225 monoclonal
.chimerized anti-EGFR was produced by ImClone
Systems, New York, NY. The secondary antibody,
peroxidase-labelled goat anti-rat IgG, was purchased
from Gibco BRL, Grand Island, NY. The turbo-TMB,
 .Iodo-Gen tubes, ImmunoPure IgG1 Fab and F ab 2
preparation kit 44880 were obtained from Pierce
Chemical Co., Rockford, IL. The 4–20% SDS-PAGE
redi-gels and the Bradford protein assay reagent were
 .from Bio-Rad Hercules, CA . Amino acid analysis
was performed on hydrolysed aliquots of C225-con-
taining samples at the Protein Structure Laboratory of
University of California, Davis. The particle size of
liposomes and immunoliposomes was measured by
dynamic light scattering Coulter N4MD, Hialeah,
.FL . Phospholipid concentrations were measured by
w xphosphorus determination 30 .
2.2. Liposome preparation
Liposomes were formulated from HSPC, choles-
 .terol mole ratio, 57:38 , and PEG–lipid conjugates
combined mPEG-DSPE and Hz-PEG-DSPE, 5
.mole% . The molar ratio of the above components
was maintained as 57:38:3.3:1.7 after the optimiza-
tion of the conjugation protocol. The liposomes were
prepared by solvent evaporation, hydration in 10 mM
desferoxamine mesylate in isotonic saline 0.9%
.NaCl solution, and extrusion through 0.2-, 0.1- and
0.05-mm membranes down to approximately 100 nm,
according to the previously published protocols
w x31,32 . The external buffer was exchanged for 0.1 M
acetate buffer pH 5.5 by dialysis.
Radiolabelling of liposomes as well as immunoli-
posomes with 67Ga-oxine resulting in entrapment of
the label by desferoxamine chelation in the liposomal
aqueous compartment was achieved as previously
w xdescribed 33 .
2.3. Iodination of antibody
Iodo-Gen tubes were prepared according to manu-
facturers instructions and stored at 48C. The C225
 .antibody solution 200 ml, 1.6 mgrml in acetate
 .buffer 0.1 M, pH 5.5 was added to a prerinsed
125  .Iodo-Gen, followed by Na I 37 mBq . After incu-
bation for 1 h the contents of the tube were trans-
ferred to a G25-80 spin column and spun for 2 min at
1500 rpm at room temperature to remove any unre-
acted 125I.
2.4. Preparation of immunoliposomes
(2.4.1. Small-scale optimization experiments see Table
)1
 .A solution of C225 IgG 100 ml at 1.6 mgrml in
 .acetate buffer 0.1 M, pH 5.5 was spiked with
125  .I-labeled antibody 5 ml . It was then treated with
an appropriate amount of sodium periodate stock
 .solution 100 mM and incubated under conditions
indicated in Table 1. At the end of the oxidation
period the excess periodate was quenched by the
 .addition of NAM solution 10 ml at 500 mM . The
oxidized antibody was mixed with hydrazide-contain-
 .ing liposomes 100 ml at 35 mmol phospholipidrml
in the acetate buffer and the reaction mixture was
incubated overnight at 68C. The conjugate was sepa-
rated from the free antibody on Sepharose CL-4B.
Column fractions were counted on a gamma counter
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Table 1
Optimization of conjugation conditions a
b c dHz content Oxidation time Oxidation temperature Periodate concentration % of conjugated IgG % increase in size
 .  .  .  .mole% min 8C mM
5 60 25 10 99 88
5 60 25 6 95 85
5 60 25 4 95 82
5 60 25 2 94 36
5 40 25 10 91 85
5 20 25 10 94 87
5 60 6 10 93 41
5 20 6 2 79 32
1.7 20 6 2 70 25
1.7 20 6 2 73 21
a Detailed procedure is given in Section 2.
b Liposomes composed of HSPC, cholesterol, and Hz-PEG-DSPE in molar ratio of 57:38:5, except for the last two entrees, where
 .liposomes contained both mPEG-DSPE and Hz-PEG-DSPE 3.3 and 1.7 mole%, respectively without alterations in the other
components.
c  .Determined from the integration of chromatographic trace see Fig. 2 .
d  .Increase in particle size of the parent liposomes ;100-nm diameter resulting from the conjugation process.
and the percent of conjugated antibody was calcu-
lated by dividing the counts in the liposomal peak by
 .the total counts loaded on the column Fig. 2 . Parti-
cle size was determined by dynamic light scattering.
(2.4.2. Preparation of immunoliposomes preparati˝e
)procedure
 .A solution of C225 antibody 5.5 ml, at 3 mgrml
was incubated with sodium periodate 2 mM, final
.  .concentration in acetate buffer 0.1 M, pH 5.5 at
Fig. 2. Size-exclusion chromatography separation on Sepharose
CL-4B column of the 125I-labeled C225 antibody eluting in
liposomal peak from the free unconjugated protein.
 .68C, for 20 min. NAM 0.5 ml of 500 mM was
w xadded to quench the excess periodate 32 . Hydra-
 .zide-liposomes 5.6 ml at 47 mmol phopholipidrml
in the same buffer were added to the solution, and the
mixture was incubated overnight at 68C. Separation
of the immunoliposomes from the free antibody was
performed on a 2.5=80 cm Sepharose CL-4B size
 .exclusion column Pharmacia . The immunoliposome
fractions were pooled and the average number of
antibody molecules per liposome was calculated from
the results of amino acid analysis and phosphate
analysis as summarized in Table 2.
2.5. Determination of antigen-binding acti˝ity
DU145 androgen-independent prostate carcinoma;
. EGFR-positive and A431 epidermoid carcinoma;
.EGFR-positive were obtained from the ATCC
 .Rockville, MD and routinely grown in RPMI-1640
medium supplemented with 10% fetal bovine serum
 .Intergen, Purchase, NY , 2 mM L-glutamine and
antibiotics.
FACS analysis: DUI45 cells human prostate car-
.cinoma, androgen-independent EGFR expressing
were removed from T-flasks with 2 mM EDTA,
washed with serum-free Dulbecco’s modified Eagle’s
 .medium containing 1% BSA D-BSA and added to
 . 6glass tubes at a concentration of 0.5–1.0 =10
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Table 2
Determination of immunoliposome composition by Amino Acid
 .Analysis AAA
Amino Residuesr nmolrAAA nmol IgGrAAA
acid C225 injection injection
Asp 118 7.041 0.0597
Thr 104 6.508 0.0626
Ser 161 9.759 0.0606
Pro 96 5.56 0.0579
Ala 67 3.656 0.0546
Val 119 7.003 0.0588
Ile 38 2.253 0.0593
Leu 109 6.49 0.0595
Tyr 58 3.405 0.0587
Phe 48 2.888 0.0602
Lys 82 5.387 0.0657
Arg 38 2.204 0.0580
An aliquot of immunoliposome solution was hydrolysed in 6 N
HCl, and then subjected to a standard amino acid analysis
protocol. The following amino acids were excluded from the
calculation: Glu, Gly, Met, His. The amino acid composition of
C225 is listed in the second column. The values in the third
column obtained directly from the AAA integration, were divided
by the corresponding values in the second column. This provided
the amount of each amino acid in nmol IgG units fourth
.column . Averaging of the numbers in the right column provided
the amount of 0.06 nmol IgG per AAA injection. This value
adjusted for dilutions leads to the concentration of the immunoli-
posome solution aliquots of which were submitted for both
phosphate and amino acid analysis 2.4 nmol IgGrmls10 mmol
.phospholipidrml . Thus the mole ratio of IgGrphospholipid was
y4  .2.4P10 38.4 mg proteinrmmol phospholipid . Assuming
75,000 phospholipid molecules per vesicle of 100 nm, this ratio
corresponds to 18 IgG residuesrliposome.
cellsrtube. For direct binding studies, C225, im-
munoliposomes, parent liposomes, or irrelevant hu-
 .man IgG Sigma were added at a concentration of 20
mg proteinrtube for 60 min on ice. After washing,
goat anti-human IgG conjugated to FITC Tago,
.Burlingame, CA was added for an additional 30 min
on ice. For competitive inhibition experiments, cells
were first incubated with immunoliposomes, parent
liposomes, human IgG, or C225 at a concentration of
20 mg proteinrtube for 30 min on ice followed by
FITC-labelled C225 5 mgrtube; a gift of Dr. N.
.Giorgio, ImClone Systems for an additional 60 min.
Both sets of samples were analyzed for cell surface
fluorescence using a Coulter Epics ELITE sorter.
Results are presented as the Mean Fluorescence In-
 .tensity MFI which is an indirect measure of antigen
w xexpression and relative affinity 34,35 . MFI is deter-
mined by dividing the percent positive cells by the
mean channel of fluorescence.
2.6. FabX fragment preparation
The C225-derived FabX fragment was obtained
 X.using the ImmunoPure IgG1 Fab and F ab prepara-2
 .tion kit Pierce, Rockford, IL following the instruc-
tions provided with the kit. Briefly, a solution of
C225 antibody 1 mg in 0.5 ml digestion buffer
.containing 10 mM cysteine was loaded onto a Ficin
immobilized column and incubated for 5 h at 378C.
The Fc portion and undigested antibody were re-
moved by protein A column chromatography. The
purity of the Fab fragment was checked by SDS-
PAGE using 4–20% polyacrylamide gels in elec-
trophoresis buffer 25 mM Tris, 250 mM glycine,
.0.1% SDS, pH 8.3 . Samples were electrophoresed
under non-denaturing conditions at 100 V for 2 h and
visualized by Coomasie blue staining. This revealed a
single band of 50–55 kDa corresponding to the FabX
product. Under reducing conditions SDS-PAGE pro-
duced single-band of approximately 25 kDa. The
concentration of the Fab product was determined by
Bradford protein assay, using BSA as a standard. The
 .yield of the process was 0.28 mg 42% .
2.7. Determination of anti-C225 antibody titers and
cross-reacti˝ity of antisera
The antibody titers in rat serum samples were
analyzed by sandwich ELISA at room temperature
using Immulon 1 microtiter plates. First the plates
were incubated with a tested protein C225 antibody,
C225-derived FabX, human IgG, or irrelevant protein,
.  .BSA solution 10 mgrml, 100 ml per well for 2 h.
The plates were washed twice with PBS, treated with
 .blocking buffer 1% normal rat sera in PBS for 2 h,
and then washed again twice with PBS. Diluted sera
 . 1:100 from immunized animals was added 100 ml
.per well . The plates were incubated for 1 h, and then
washed with PBSr0.5% Tween-20 to remove the
unbound protein. Then a peroxidase-labelled goat
anti-rat IgG solution 100 ml, diluted 1:20,000 in the
.blocking buffer was added to each well. The plates
were incubated again for 1 h. The unbound antibody
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Table 3
Tissue distribution at 24-h post-dose of C225, parent liposomes
and conjugates thereof in percent of injected dose per tissue a
Sample Liver Spleen Blood
bParent liposomes 11.0"1.5 8.4"1.1 45.1"3.6
cFree C225 3.0"0.2 0.2"0.0 39.1"4.7
Immunoliposomes:
10 IgGrvesicle 32.5"4.0 11.9"1.6 16.3"1.7
18 IgGrvesicle 21.8"2.2 24.3"1.7 3.7"0.6
24 IgGrvesicle 30.1"2.6 18.0"4.9 3.1"0.9
40 IgGrvesicle 34.5"3.9 6.1"0.9 0.6"0.1
a Other tissues sampled heart, kidneys, lungs, skin, bone and
.muscle routinely contained less than 1.5% of the injected dose.
b Repeated injections or coinjections with C225 antibodies yielded
the same tissue distribution.
c Repeated injections or coinjections with parent liposomes
yielded the same tissue distribution.
was removed by washing with the PBSrTween-20
solution. The signal was measured by addition of
 .substrate, Turbo-TMB solution 100 ml to each well
and incubating for 10 min. The reaction was termi-
nated by addition of sulfuric acid 2 M, 50 ml per
.well . The plates were read at 450 nm on a plate
reader.
2.8. Animal experiments
In vivo studies were conducted using adult male
 .Sprague Dawley rats 250–400 g that were dosed by
bolus tail vein injection. Single-dose pharmacokinetic
and biodistribution studies utilized 4 animals per
experiment. Subsequent repeated-dose immunogenic-
ity studies utilized 16–20 animals per experiment to
 .enable interim sacrifices 4–6 rats per sacrifice after
each dose for tissue distribution evaluations. The
appropriately radiolabelled samples C225, parent li-
.posome, mixture thereof, or immunoliposome pre-
pared in isotonic saline were administered intra-
venously at a dose of approximately 10–20 mmol
phospholipidrkg body weight. Blood levels at vari-
ous times were determined by retro-orbital bleeding
while tissues were obtained surgically 24-h post-dose.
Tissue and blood levels of 67Ga andror 125I radioac-
tivity were determined using a Beckman 5500 gamma
 .counter Table 3 . Radioactivity in blood and tissue
samples were converted into percent of injected dose
units. For immunogenicity experiments the animals
were subjected to three repeated i.v. injections on
days 0, 14, and 28. Serum samples were obtained at
 .selected time points see Fig. 7 by collecting whole
blood on ice, and removing the blood cells by cen-
Table 4
Pharmacokinetic parameters
Sample MRT AUC T b Cl0“ 0 1r2“
 .  .  .  .h % dose hrml h mlrh
aParent liposomes 37.6"1.0 2686.0"165.5 19.1"0.6 0.037"0.002
bFree C225 39.5"9.4 2942.0"605.2 27.7"6.5 0.035"0.007
Immunoliposomes:
10 IgGrvesicle 20.3"2.1 1104.9"106.4 14.3"1.6 0.091"0.009
c18 IgGrvesicle
Dose 1 8.6"0.5 495.4"51.0 6.4"0.4 0.20"0.02
dDose 2 0.7"0.2 13.9"1.1 0.5"0.1 7.23"0.54
dDose 3 0.4"0.1 12.8"1.6 0.3"0.1 7.92"0.88
24 IgGrvesicle 9.3"0.6 362.0"83.6 7.0"0.5 0.29"0.07
40 IgGrvesicle 7.6"0.6 98.1"14.9 6.5"0.8 1.04"0.16
a Repeated injections or coinjections with C225 antibodies yielded the same clearance curves and pharmacokinetic parameters.
b Repeated injections of 125I-labeled C225 antibodies or coinjections with parent liposomes yielded the same clearance curves and
pharmacokinetic parameters.
c Repeated injections of immunoliposomes yielded significantly different circulation times after the second and third administration.
d The clearance rate of the immunoliposomes after the second and third injections was mono-expontial.
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trifugation after allowing 20 min for clotting. Phar-
macokinetic analysis of concentration vs. time data
was performed using noncompartmental methods with
the RSTRIP program Micromath, Salt Lake City,
.UT . The software provides values for areas under
 .  .the zero AUC and first moment AUMC concen-
tration curves from which the derived parameters
 .Table 4 were calculated. Mean residence time
 .MRT , the time it takes to eliminate 63.2% of the
administered dose, was derived by the formula: MRT
 .sAUMCrAUC, while total clearance Cl was de-
termined by dividing dose by AUC.
3. Results and discussion
3.1. Preparation of immunoliposomes
Immunoliposomes were prepared by coupling peri-
odate-oxidized C225, IgG to hydrazide-PEG-DSPE
containing liposomes. As schematically depicted in
Fig. 1, hydrazone attachments are formed between
aldehyde-bearing oxidized IgG and hydrazide end
groups on the periphery of the liposome. Im-
munoglobulin conjugation utilizing the specific reac-
tivity of their oxidized carbohydrate residues has
w xbeen known to produce active adducts 36–38 . This
is explained by the fact that the conjugation occurs
site-specifically via the oligosaccharide moieties posi-
tioned on the Fc portion of the glycoprotein molecule,
w xfar away from the antigen binding sites 38,39 . Our
initial experiments showed that the coupling condi-
tions used in some of our previous studies with other
w ximmunoglobulins 7,11,15,40,41 produced severe ag-
gregation of the immunoliposomes. This was mani-
fested by considerable increase in the particle size of
the product. By gradually moderating the conditions
of the conjugation reaction, as summarized in Table
1, we arrived at a final procedure which was used for
the remainder of this study last two entries in Table
.1 . These optimization experiments were monitored
by particle size measurements and size-exclusion
chromatography, which allowed us to determine how
much of the total 125I-IgG was eluted in the liposomal
 .peak Fig. 2 . Since the starting liposomes were on
average 100 nm in diameter, and IgG molecule can
˚ w xbe viewed roughly as a 100-A sphere 42 , an approx-
imately 20% increase in size as a result of conjuga-
tion was judged as reasonable. The final optimized
conditions included oxidation of the antibody at 68C,
with 2 mM periodate for 20 min and then conjugation
with liposomes containing only 1.7 mole% of Hz-
PEG-DSPE the rest of the components, HSPC,
.cholesterol, mPEG-DSPE, in molar ratio 58:38:3.3 .
These oxidation conditions closely approximate those
reported to specifically modify sialic acid residues,
and they are unusually mild for conjugation of im-
w xmunoglobulins 39 .
3.2. Single-dose pharmacokinetics of immunolipo-
somes
Varying the amount of oxidised C225 and its ratio
to hydrazide-bearing liposomes we prepared samples
containing 10, 24, and as many as 40 IgG residues
per vesicle. Pharmacokinetic characteristics of these
preparations and the parent liposomes were evaluated
in rats after radiolabelling the liposomal aqueous
67 w xcompartment with Ga-desferal 33 . As can be seen
from Fig. 3A increasing the amount of bound anti-
body per vesicle facilitated faster clearance from
blood circulation. Labelling the IgG with 125I-label in
addition to the 67Ga in the aqueous compartment, and
following the fate of both markers in blood showed
 .identical pharmacokinetic profiles Fig. 3B . This
result suggests that the immunoliposomes remained
intact for the duration of the experiment. Tissue
distribution at 24 h post injection from these experi-
ments is summarized in Table 3, while the pharma-
cokinetic parameters are summarized in Table 4.
These data show that the hepatosplenic uptake was
markedly increased for faster-clearing immunolipo-
some formulations. Moreover, these results are in
agreement with the previous observations that attach-
ment of increasing amounts of immunoglobulin
w x w x9,10,41 , or even low-molecular-weight peptide 32 ,
to the periphery of PEG-grafted liposomes results in
faster clearance from systemic circulation. In order to
balance prolonged circulation lifetime with a reason-
ably high antibody density, based on the pharmacoki-
netic curves depicted in Fig. 3A, we decided to use
10–24 IgG per vesicle in the subsequent studies.
3.3. Antigen binding acti˝ity
Preservation of antigen-binding activity of the im-
munoliposomes was corroborated by both direct and
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Fig. 3. Pharmacokinetic profiles of parent and C225-bearing
 .  .liposomes mean"SD . Four rats per experiment. A Blood
clearance rates of 67Ga-labeled liposomes carrying various
 .amounts of C225 antibody. B Comparison of plasma clearance
curves obtained by following 67Ga-aqueous compartment label,
and 125I-conjugated C225 label of immunoliposomes containing
f10 IgG residues per liposome.
competitive binding assays using DU145 cells
EGFR-positive, androgen-independent prostate car-
.cinoma . Both methods produced results consistent
 .with each other Fig. 4 . Similar antigen-binding
activities were observed with A431 cells EGFR-
.positive, epidermoid carcinoma, data not shown . The
direct assay results suggest somewhat lower activity
of the immunoliposomes in comparison to the free
C225. Although the possibility that the antigen-bind-
ing affinity was diminished by the conjugation cannot
be excluded, in light of the mildness of our conjuga-
tion conditions it seems more likely that the binding
of the liposomal conjugate to the cells was affected
by the size of the conjugate or accessibility of its Fc
residues. The latter factor is important in quantitation
of the EGFR-positive cell-bound immunoconjugate
using goat anti-human FITC-linked IgG. In fact de-
tection of antigen binding using this method might be
in contrast to what could have been expected, be-
cause it suggests that despite our use of Fc-directed
site-specific conjugation method, the Fc residues of
the resulting immunoliposomes were still exposed to
a measurable extent.
3.4. Immunogenicity studies
All the above pharmacokinetics experiments Fig.
.3 involved only a single i.v. injection per formula-
Fig. 4. Antigen-binding activity of immunoliposomes f13 IgG
.residues per vesicle of 100 nm to EGFR-positive DU145 cells.
The cells were treated, as detailed in experimental section, with:
 .  .A for direct binding assay: human IgG1 hu IgGl-D , C225
 .  .C225-D , immunoliposomes C225-lipo-D , or parent liposomes
 .free lipo-D and probed with goat ant-human IgG conjugated to
 . FITC; and B for competitive assay: human IgGl hu IgGlq
.  . C225-F , C225 C225qC225-F , immunoliposomes C225-lipo
.  .qC225-F , or parent liposomes free lipoqC225-F and probed
 .with FITC conjugated C225 C225-F . The C225-F-labeled bar
represents positive control. Samples were analyzed by flow cy-
tometry and the results are expressed as the Mean Fluorescence
 .Intensity MFI .
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tion per animal. Under these conditions the immune
response, even if induced, would not have an oppor-
tunity to influence the pharmacokinetics of the im-
munoliposomes since measurements were only taken
over a 24-h period. Although single injections of
immunoliposomes might be adequate for diagnostic
purposes, to be useful for targeted drug delivery
repeated administrations in many instances would be
advantageous. In light of these considerations and to
address the issue of immunoliposomes’ immuno-
genicity and its relationship to their pharmacokinetic
behavior, the following experiments were designed.
Animals were given three injections of either the
immunoliposomes, or free C225, or a mixture of
parent liposomes and C225, each formulation given
on days 0, 14, and 28. A separate group of four rats
was treated with immunoliposomes, on day 0, and
then injected with free C225 on days 14 and 28.
Pharmacokinetic curves generated from these experi-
ments are shown in Figs. 5 and 6. Blood samples
taken from the tested animals at various time points
were used for determination of anti-C225 titers. These
results are summarized in Fig. 7. These experiments
demonstrate that the subsequently injected immunoli-
posomes were cleared much faster from the blood-
stream than the ones administered initially see the
clearance rate constants and other pharmacokinetic
.parameters in Table 4 . This accelerated clearance
correlated with significant increase in C225-specific
antisera in the animal plasma. In contrast, repeated
injections of the free immunoglobulin or a mixture of
C225 with the parent liposomes did not trigger any
detectable response as demonstrated by the overlap-
 .ping clearance curves Fig. 5B and 6 and negligible
 .anti-C225 titers generated Fig. 7A . Further evidence
indicating that the injection of immunoliposomes was
responsible for the anti-C225 specific response came
from the experiments subjecting immunoliposome-
pretreated animals to injections with free C225. As
can be seen from Fig. 5B, administration of the free
immunoglobulin showed the same pharmacokinetic
behavior after each injection, except when injected
into immunoliposome-pretreated animals. The latter
group of rats had a similar anti-C225 serum reactivity
to animals treated with immunoliposomes only Fig.
.7B . These results would be expected from C225
preimmunized animals. Note that all the animals
subjected to the three repeated injection regiments,
Fig. 5. Blood clearance curves obtained following each dose of
 .  . 67A three repeated injections on days 0, 14 and 28 of Ga-
labeled immunoliposomes f18 C225 residues per vesicle of
.  .  .100 nm ; and B three repeated injections days 0, 14 and 28 of
125  .I-labeled free C225-antibody 3 upper curves , and two injec-
 . 125tions days 14 and 28 of free I-labeled C225-antibody into
 .animals, which received one injection day 0 of the immunolipo-
 .  .somes lower 2 curves . Four rats per experiment mean"SD .
appeared to be healthy, gained weight and exhibited
no abnormal behavior.
These results are in accord with the observations
w xpreviously made by Phillips et al. 25 who prepared
avidin–biotin conjugated liposomes bearing GK1.5
rat IgG, and reported significant levels of anti-GK1.5
neutralizing antibodies forming after i.v. administra-
tion of these immunoliposomes in mice, regardless of
whether mPEG–lipid components were present in the
formulations. In contrast, we used site-specific conju-
gation approach yielding homogeneous immunolipo-
somes of a well-defined composition. Thus despite
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Fig. 6. Blood clearance curves obtained following three coinjec-
tions of 125I-labeled free C225-antibody and 67Ga-labeled parent
 .  .liposomes. Four rats per experiment mean"SD . A Pharma-
cokinetic profiles of each injection following 67Ga-label of lipo-
 .somes. B Pharmacokinetic profiles of each injection following
125I-label of C225.
the significant differences in our experiments in
methodology, composition, and homogeneity of the
immunoliposome preparations, both studies confirm
the immunogenic properties of PEG-containing im-
munoliposomes.
The C225 antibody is a chimerized mouse IgG and
 .thus composed of a constant human portion Fc and
 .variable mouse portions Fab . It was important to
find out to what extent the observed immune re-
sponse was elicited by each of these regions of the
conjugated C225. For this purpose selected serum
samples from immunoliposome-treated animals were
tested for binding to polyclonal human IgG and the
 .C225-derived Fab fragment Fig. 8 . The signals
obtained from human IgG-coated ELISA plate wells
were almost the same as from intact C225-coated
wells. In contrast, little antiserum binding was ob-
served to the Fab portion of the antibody. These
results demonstrate that the immune response to
C225-liposomes was triggered primarily by the con-
stant human region of the covalently attached anti-
body. This indicates that the observed potentiation of
C225 immunogenicity as a result of its fixation to
 .Fig. 7. Anti-C225 specific titers obtained by ELISA. A Analy-
sis of plasma samples from three groups of rats treated with
either immunoliposomes, or free C225, or with coinjection of
 .C225 with the parent liposomes. B C225 specific antisera
detected in plasma of animals treated first with immunoliposomes
 .  .day 0 and then twice days 14 and 28 with free C225.
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Fig. 8. ELISA analysis of antiserum binding to human polyclonal
IgG, C225-derived Fab’. For comparison binding to intactrwhole
C225, and an irrelevant protein, BSA are shown. Plasma samples
obtained from C225-liposome treated rats at indicated times.
PEG-liposomes was almost exclusively due to the Fc
portion of the C225 molecule and little if any was
due to the Fab parts.
3.5. Summary and conclusions
Our results demonstrate a straightforward method-
ology for preparation of PEG-grafted liposomes bear-
ing C225 IgG residues attached to the termini of the
external surface-grafted polymer chains. The method-
 .ology described has several promising attributes: 1
efficient conjugation procedure under very mild con-
 .ditions; 2 composition of the immunoconjugates
 .can be readily controlled; and 3 antigen-binding
activity of the conjugates is well preserved. Although
repeated i.v. administration of free chimerized mouse
IgG, C225, into rats did not trigger an immune
response, a single injection of C225-containing im-
munoliposomes did. This suggests that a potentiation
of immunogenic properties occurred as a result of the
covalent fixation of the IgG to the polymer-grafted
liposomes. This conclusion was further corroborated
by C225-specific IgG titers. The antiserum recog-
nized readily human polyclonal IgG, yet it hardly
recognized the Fab fragment of C225, indicating that
the immunogenicity potentiation was specific to the
constant human, Fc region of C225. The appearance
of C225-specific antibodies in the immunoliposome-
treated rats was manifested by a dramatically acceler-
ated clearance from the bloodstream of the subse-
quently injected immunoliposomes or free C225.
Somewhat surprisingly, in our experiments the free
C225 IgG behaved as an antigen, but was not im-
munogenic. We would like to emphasize that at this
point it is not clear how general the phenomenon of
enhanced immunogenicity of PEG-liposome linked
antibody is. Further experimentation should shed light
on this question. Moreover, since we detected only a
slight immune response to the Fab portion of conju-
gated C225, there might be further merit in evaluat-
ing Fab-fragments as targeting moieties for PEG-
w xliposomes 43 . Our observations indicate that the
potential for induction of immune response should be
seriously considered in the development of long-cir-
culating formulations of immunoliposomes as drug
delivery vehicles, since at least the whole antibody
conjugates of PEG-liposomes are probably immuno-
genic. The immunogenicity or lack thereof is bound
to be crucially important in influencing the longevity
in blood circulation of such constructs and their
ability to reach their intended target sites.
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